Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):293-296. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0101

View: 609 Download: 28

Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):276-278. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0220

View: 768 Download: 15

Original Article

Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation

Ying-Nan Tsai, Jia-Ling Wu, Cheng-Hao Tseng, Tzu-Haw Chen, Yi-Ling Wu, Chieh-Chang Chen, Yu-Jen Fang, Tzeng-Huey Yang, Mindie H. Nguyen, Jaw-Town Lin, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(1):98-108. Published online December 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0194

View: 1681 Download: 137 Web of Science: 1 Crossref: 5

Review

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka

Clin Mol Hepatol. 2023;29(4):851-868. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0434

View: 6759 Download: 353 Web of Science: 6 Crossref: 9

Novel biomarkers for the management of chronic hepatitis B

Takako Inoue, Yasuhito Tanaka

Clin Mol Hepatol. 2020;26(3):261-279. Published online June 15, 2020

DOI: https://doi.org/10.3350/cmh.2020.0032

View: 14668 Download: 694 Web of Science: 71 Crossref: 73

1 |

Viewed By 5412	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5377	MAFLD: How is it different from NAFLD?
Viewed By 5267	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3935	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3921	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search